Peter discusses the shift in pharma companies acquiring early-stage technology, leading to lucrative exits for venture backers. The decrease in internal research in pharma has spurred external R&D investments, resulting in innovative startups and quick acquisitions. The changing landscape presents exciting opportunities for venture investors in life sciences.
